Azithromycin versus standard care in patients with mild-to-moderate COVID-19 (ATOMIC2): an open-label, randomised trial경증에서 중등도의 CovID-19 (Atomic2) 환자의 아지트로 마이신 대 표준 치료 : 개방형, 무작위 시험Randomized Controlled Trial Published on 2021-10-012022-08-13 Journal: The Lancet. Respiratory Medicine [Category] MERS, SARS, 임상, [키워드] 1:1 adjusted age Anti-inflammatory Antibacterial antiviral properties antiviral property assigned Azithromycin clinically Confirmed COVID-19 infection Consent COVID-19 COVID-19 infection death diagnosed did not reduce died effective enrolled finding funding hospital Hospital admission initial intention-to-treat principle management Mild-to-moderate mild-to-moderate disease once daily Open-label outcome Oxford participant Patient Pfizer presenting Primary outcome randomisation randomised Randomised trial Randomly recruitment reducing Registered removal reported risk Serious Adverse Event Serious Adverse Events standard care standard care group subsequent Support Symptoms therapeutic potential Treatment Trial University of Oxford was done were assessed [DOI] 10.1016/S2213-2600(21)00263-0 PMC 바로가기 [Article Type] Randomized Controlled Trial
Effects of Shuanghuanglian oral liquids on patients with COVID-19: a randomized, open-label, parallel-controlled, multicenter clinical trialCOVID-19 환자에 대한 Shuanghuanglian 경구 액체의 효과: 무작위, 공개, 병행 대조, 다기관 임상 시험Randomized Controlled Trial Published on 2021-10-012022-09-11 Journal: Frontiers of medicine [Category] SARS, 유전자 메커니즘, 임상, [키워드] 95% CI Absorption addition baseline Chest computed tomography Chinese clinical trial Combination composed Computed tomography conducted control group COVID-19 disease dose Effect effective evaluated groups High dose High-dose Inflammatory low dose mean difference multicenter Multicenter trial Negative conversion nucleic acid occurred Open-label Patent Medicine Patient Pneumonia promoted Randomized reduction Safe SARS-CoV-2 Serious Adverse Event Serious Adverse Events Shuanghuanglian oral liquid significantly significantly higher standard care Standard therapy Swab test the patient Treatment [DOI] 10.1007/s11684-021-0853-6 PMC 바로가기 [Article Type] Randomized Controlled Trial
Clinical efficacy and safety of Janus kinase inhibitors for COVID-19: A systematic review and meta-analysis of randomized controlled trialsCOVID-19에 대한 Janus kinase inhibitors의 임상적 효능 및 안전성: 무작위 대조 시험의 체계적인 검토 및 메타 분석Meta-Analysis Published on 2021-10-012022-09-11 Journal: International immunopharmacology [Category] SARS, 신약개발, 임상, [키워드] 95% CI adverse event all-cause mortality rate And tofacitinib Baricitinib clinical Clinical efficacy Clinical outcome clinical recovery ClinicalTrials Control Controlled controlled trials controls COVID-19 COVID-19 patients Efficacy and safety hospitalized COVID-19 patients inception inhibitor Invasive mechanical ventilation Jak JAK inhibitor jak inhibitors janus Janus kinase Janus kinase inhibitor Kinase inhibitor Meta-analysis mortality rate no significant difference Placebo Primary outcome Randomized controlled trial Randomized controlled trials RCT RCTs receiving risk ruxolitinib Safe searched Serious Adverse Event Serious Adverse Events standard care systematic review the patient Time to recovery Tofacitinib treating COVID-19 patient Treatment [DOI] 10.1016/j.intimp.2021.108027 PMC 바로가기 [Article Type] Meta-Analysis
Hydroxychloroquine for the treatment of severe respiratory infection by COVID-19: A randomized controlled trialCovid-19에 의한 심각한 호흡기 감염 치료를위한 하이드 록시 클로로 퀴인 : 무작위 대조 시험Randomized Controlled Trial Published on 2021-09-282022-09-10 Journal: PLoS ONE [Category] SARS, 임상, 치료제, [키워드] 30-Day mortality 95% confidence interval analyzed both groups confidence COVID-19 cumulative cumulative incidence demonstrated double-blind Efficacy evaluate hazard ratio health problem Hospital mortality Hospitalization hospitalized patient hospitalized patients Hydroxychloroquine hypoxemic in both group in-hospital mortality incidence intention-to-treat analysis interval low dose Lung injury material mechanical ventilation Mortality no significant difference Novel coronavirus outcome pandemic Participants patients patients with COVID-19 Placebo placebo-controlled trial Primary outcome public health Pulse rate randomization Randomized Randomized controlled trial recruited reduce respiratory Respiratory disease Result RT-PCR secondary Secondary outcomes Serious Adverse Events severe COVID-19 severe disease severe respiratory disease severe respiratory infection subject Treatment with COVID-19 [DOI] 10.1371/journal.pone.0257238 PMC 바로가기 [Article Type] Randomized Controlled Trial
Endobronchial valve positioning for alveolar-pleural fistula following ICU management complicating COVID-19 pneumoniaCase Report Published on 2021-09-272022-10-28 Journal: BMC Pulmonary Medicine [Category] COVID-19, Fulltext, SARS, [키워드] acute respiratory syndrome affected Alveolar-pleural fistula ARDS Bacterial clinical consequence complex interaction coronavirus 2 COVID-19 EBV effective Endobronchial Endobronchial valve feasible ICU Infection Inflammation Injury invasive Invasive mechanical ventilation Klebsiella pneumoniae lung parenchyma lung tissue management mechanical ventilation Patient patients persistent Pneumonia Pneumothorax Respiratory failure SARS-CoV-2 Serious Adverse Events severity Stage subset therapeutic option treated [DOI] 10.1186/s12890-021-01653-w PMC 바로가기 [Article Type] Case Report
The Effectiveness of Convalescent Plasma for the Treatment of Novel Corona Virus Disease 2019: A Systematic Review and Meta-AnalysisMedicine Published on 2021-09-272022-10-31 Journal: Frontiers in Medicine [Category] COVID-19, [키워드] 28-day mortality 95% CI Analysis antibody CBM CCP CNKI conducted control group convalescent plasma Corona Coronavirus disease 2019 COVID-19 criteria Critical critical COVID-19 patient Efficacy and safety enrolled Evidence group hospital Hospital stay ICU ICU admission incidence Infection Inflammatory Intervention mechanical ventilation Meta-analysis Mortality mortality rate no significant difference novel Novel coronavirus overall mortality participant Patient patients with COVID-19 PICOS Placebo placebo group plasma Primary outcome Randomized controlled trial RCT RCTs reduce reducing review safety and efficacy searched secondary outcome Serious Adverse Events significant difference significantly significantly shorter SSRN subgroup analysis subject therapy Treatment treatment group treatments of COVID-19 VIP viral loads Web of Science worldwide pandemic [DOI] 10.3389/fmed.2021.641429 PMC 바로가기 [Article Type] Medicine
Weekly 17 alpha-hydroxyprogesterone caproate to prevent preterm birth among women living with HIV: a randomised, double-blind, placebo-controlled trial주간 17 Alpha-HydroxyProgesterone CABROATE HIV를 가진 여성들 사이에서 조산을 예방하기위한 : 무작위, 이중 맹검, 위약 대조 시험Articles Published on 2021-09-092022-09-06 Journal: The Lancet. HIV [Category] Communicable Disease, [키워드] 1:1 17P 95% CI adherence adverse event adverse events age Anomaly antenatal care Antiretroviral therapy assessments assigned available data baseline characteristics both groups Cervical cerclage Characteristics Complete Composite criteria District double-blind drug during pregnancy early delivery Eligible participants eligible patient Eligible patients enrolled event Evidence evidence of except for exclusion criteria fetal Final finding Follow-up for inclusion foundation funding gestation gestational age group groups HIV infection HIV-1 infection in both groups in some increased risk injection Intention intention to treat intramuscular investigated less Melinda Gate Melinda Gates membrane miscarriage occurred Older participant Participants Patient Placebo placebo-controlled trial Pregnancy pregnant women Preterm birth Prevent Primary outcome proportion provided random assignment randomisation randomised Randomly receive receiving reduce Registered Relative risk reported risk risk difference Safe Serious Adverse Event Serious Adverse Events shown Stillbirth study drug Support Teaching treatment group treatment groups Trial university uterine Weekly were excluded with HIV women written Informed Consent [DOI] 10.1016/S2352-3018(21)00150-8 PMC 바로가기 [Article Type] Articles
Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial영국 지역 사회에서 합병증의 위험이 높은 사람들의 Covid-19에 대한 흡입 부데소니드 (원칙) : 무작위, 제어, 오픈 라벨, 적응 형 플랫폼 시험Randomized Controlled Trial Published on 2021-09-042022-08-13 Journal: Lancet (London, England) [Category] MERS, SARS, 임상, [키워드] absolute difference Adaptive platform trial Admission analysed assigned Bayesian credible interval Bayesian models BCI benefit Budesonide chance Community Comorbidities Complication complications COVID-19 COVID-19 in patient credible interval death Effectiveness Efficacy eligible Eligible participants Endpoint enrolment estimated rate finding funding greater hazard ratio high risk higher risk hospital Hospital admission Hospital admissions IMPROVE include individual inhaled budesonide inhaled budesonide reduce Innovation ISRCTN ISRCTN registry multi-arm multicentre Odds ratio Older Open-label other treatment other treatments outcome participant people with COVID-19 Platform trial primary analysis primary analysis population primary care Probability randomisation randomised Randomly receiving reducing Registered SARS-CoV-2-positive participant SARS-CoV-2-positive participants Serious Adverse Event Serious Adverse Events superiority criterion threshold Time to recovery Trial United Kingdom usual care usual care alone usual care group [DOI] 10.1016/S0140-6736(21)01744-X PMC 바로가기 [Article Type] Randomized Controlled Trial
Safety and Efficacy of COVID-19 Vaccines: A Systematic Review and Meta-Analysis of Different Vaccines at Phase 3Review Published on 2021-09-042022-10-28 Journal: Vaccines [Category] COVID-19, [키워드] 2019 novel coronavirus acute respiratory syndrome article Asymptomatic case asymptomatic infection caused clinical trial conducted coronavirus COVID-19 COVID-19 vaccine disease disorder dose effective Efficacy Evidence gastrointestinal complication heterogeneity Inactivated vaccine Inactivated Vaccines indicated Infection Meta-analysis mRNA vaccine mRNA vaccines Musculoskeletal non-replicating vaccines observational study Occurrence phase Prevent recipients reduce reduced renal Research retrieved review risk Safe Safety Serious Adverse Event Serious Adverse Events severity symptomatic systematic review vaccination Vaccine vaccine dose vaccine platform vessel Viral vector [DOI] 10.3390/vaccines9090989 PMC 바로가기 [Article Type] Review
SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19COVID-19 치료를 위한 SARS-CoV-2-중화 단일클론항체Review Published on 2021-09-022022-09-11 Journal: The Cochrane database of systematic reviews [Category] SARS, 변종, 임상, [키워드] 95 % CI 95% CI 95% confidence interval Admission adverse event adverse events AEs all-cause mortality antibody approach average age B cell B cells bamlanivimab Blinding Casirivimab certainty certainty of evidence checked clinical Cochrane COVID-19 Study Register Combination combination therapy conducted coronavirus disease Coronavirus disease 2019 COVID-19 Data collection database death decrease dose Effectiveness etesevimab evaluated event Evidence excluded first test GRADE hospital Hospital admission Hospital admissions hospital discharge hospitalised Host Human identify Imdevimab IMV individual individuals with COVID-19 initial Intervention Invasive mechanical ventilation investigated lack life limitation mAb mAbs maintain moderate monoclonal antibodies monoclonal antibody Mortality NCT04427501 neutralising mAbs nine no effect non-hospitalised occurred outcome oxygen Oxygen requirement participant Participants patients with COVID-19 people with COVID-19 Placebo placebo group placebo treatment potential therapy progression Prophylactic provided Quality of life randomised controlled trial RCT reduce regdanvimab reported risk risk of bia risk ratio RoB2 SAE SAEs Sample size SARS-CoV-2 variant SARS-CoV-2 variants searched Selection Serious Adverse Event Serious Adverse Events severe symptom severe symptoms slight increase Sotrovimab submission Symptom systematic review target the placebo group treat treated Treatment treatment of COVID-19 usual care usual care alone [DOI] 10.1002/14651858.CD013825.pub2 PMC 바로가기 [Article Type] Review